We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Sensitive Test Developed for Sleeping Sickness

By LabMedica International staff writers
Posted on 05 Jun 2012
Print article
Image: Trypanosoma brucei  ssp. in human blood (Photo courtesy of US Centers for Disease Control and Prevention).
Image: Trypanosoma brucei ssp. in human blood (Photo courtesy of US Centers for Disease Control and Prevention).
Proteins imitating typical parts of the sleeping sickness parasite can be used in more efficient diagnostic tests, without the need for culturing dangerous parasites.

In the regions where Trypanosoma brucei gambiense, the causative agent of sleeping sickness is found, medical workers for decades already use a rapid diagnostic test, to screen millions of people each year on the presence of antibodies in their blood.

A scientist at the Antwerp Institute of Tropical Medicine (Belgium) has developed a new and better test by trying to synthesize artificial targets. These 'mimotopes' mimic only a part of the original target protein, but still are sufficient to react with the patient's antibodies. The investigator produced mimotopes that are reliable and react with infected patients' serum. These mimotopes now can be the base for a new generation of rapid diagnostic tests for sleeping sickness.

In the original tests the antibodies are demonstrated by presenting them targets they will also recognize and attack on real trypanosomes such as the variable surface glycoprotein that cover the parasite as a mantle. When antibody and target react, the test is positive and is made visible by for instance a color change or a clotting. Today those targets are obtained from living parasites that are raised in laboratory animals, and are a constant danger for the laboratory technicians.

In an early stage, the disease is easy to treat, but once the brain is invaded, the treatment becomes more complex and physicians must use medicines with dangerous, even deadly, side effects. Therefore, it is important to detect the infection early. Patients become disoriented, their sleeping pattern disintegrates, and they get motor and mental problems. This inevitably leads to coma and death. According to the World Health Organization (WHO; Geneva, Switzerland) estimates, sleeping sickness claims 10,000 to 20,000 lives each year. In recent years, the number of cases has come down substantially, thanks to campaigns against the disease, so error margins that were acceptable in the old days, because the tests still saved so many lives, now become inadmissible.

Related Links:

Antwerp Institute of Tropical Medicine
World Health Organization


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.